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Summary
Background.  —  Few  studies  have  analyzed  the  cost  of  treatment  of  chronic  angina  pectoris,disease;
Costing  study;
Models;
especially  in  European  countries.
Aim.  —  To  determine,  using  a  modeling  approach,  the  cost  of  care  in  2012  for  1  year  of  treatment
of patients  with  stable  angina,  according  to  four  therapeutic  options:  optimal  medical  therapy
(OMT); percutaneous  coronary  intervention  with  bare-metal  stent  (PCI-BMS);  PCI  with  drug-
eluting stent  (PCI-DES);  and  coronary  artery  bypass  graft  (CABG).
Abbreviations: BMS, bare-metal stent; CABG, coronary artery bypass graft; CAD, coronary artery disease; CI, conﬁdence interval; DDD,
eﬁned daily dose; DES, drug-eluting stent; DRG, diagnosis-related group; MI, myocardial infarction; OMT, optimal medical therapy; PCI,
ercutaneous coronary intervention; PMSI, French Programme of Medicalization of Information Systems (programme médicalisé des systèmes
’informations).
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Revascularization;
Drug
Methods.  —  Six  different  clinical  scenarios  that  could  occur  over  1  year  were  deﬁned:  clinical
success; recurrence  of  symptoms  without  hospitalization;  myocardial  infarction  (MI);  subse-
quent revascularization;  death  from  non-cardiac  cause;  and  cardiac  death.  The  probability  of  a
patient being  in  one  of  the  six  clinical  scenarios,  according  to  the  therapeutic  options  used,  was
determined  from  a  literature  search.  A  direct  medical  cost  for  each  of  the  therapeutic  options
was calculated  from  the  perspective  of  French  statutory  health  insurance.
Results.  —  The  annual  costs  per  patient  for  each  strategy,  according  to  their  efﬁcacy  results,
were, in  our  models,  D  1567  with  OMT,  D  5908  with  PCI-BMS,  D  6623  with  PCI-DES  and  D  16,612
with CABG.  These  costs  were  signiﬁcantly  different  (P  <  0.05).  A  part  of  these  costs  was  related
to management  of  complications  (recurrence  of  symptoms,  MI  and  death)  during  the  year
(between  3%  and  38%  depending  on  the  therapeutic  options  studied);  this  part  of  the  expenditure
was lowest  with  the  CABG  therapeutic  option.
Conclusion.  —  OMT  appears  to  be  the  least  costly  option,  and,  if  reasonable  from  a  clinical  point
of view,  might  achieve  appreciable  savings  in  health  expenditure.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — Les  données  économiques  concernant  la  prise  en  charge  des  patients  insufﬁsants
coronariens  en  France  sont  parcellaires.
Objectif.  — Déterminer  le  coût  annuel  de  prise  en  charge  pour  l’Assurance  maladie  en  2012,  des
4 traitements  utilisés  pour  prendre  en  charge  l’angor  stable  :  médicaments  seuls,  angioplastie
avec stent  nu,  angioplastie  avec  stent  actif  et  pontage  aorto-coronaire.
Méthodes.  — Nous  avons  déﬁni  6  situations  cliniques  correspondant  aux  différents  états  dans
lequel peut  se  retrouver  un  patient  un  an  après  qu’il  ait  bénéﬁcié  d’un  des  4  traitements.  Pour
chaque situation  clinique,  des  soins  étaient  consommés  et  nous  avons  calculé  le  coût  annuel  de
chaque situation.  Nous  avons  déﬁni,  ensuite,  pour  chaque  traitement,  grâce  à  une  recherche
bibliographique,  la  probabilité  à  un  an  d’être  dans  l’une  des  6  situations  cliniques.  Ceci  nous
a permis  de  calculer  le  coût  moyen  annuel  de  chaque  traitement  en  tenant  compte  de  son
efﬁcacité.
Résultats.  —  Le  coût  moyen  annuel  était  de  D  1567  avec  le  traitement  par  médicaments,  D  5908
avec l’angioplastie  stent  nu,  D  6623  avec  l’angioplastie  stent  actif  et  D  16  612  avec  le  traite-
ment chirurgical.  Ces  coûts  étaient  signiﬁcativement  différents  (p  <  0,05).  Une  partie  des  coûts
était liée  à  la  prise  en  charge  des  complications  (hospitalisations  pour  infarctus,  revascularisa-
tion et  décès)  :  ceci  représentait  de  3  %  à  38  %  du  coût  annuel  de  chaque  traitement.
Conclusions.  —  Le  traitement  médicamenteux  était  la  stratégie  la  plus  économique  après  un  an
de suivi.  Ceci  laisse  penser  que  le  traitement  conservateur  peut  être  une  source  potentielle
d’économie.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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In  France  in  2009,  the  direct  cost,  in  terms  of  statutory
health  insurance,  of  the  long-term  disease  named  ‘‘coronary
artery  disease’’  (CAD)  (affection  de  longue  durée  no 13
« maladie  coronarienne  »)  was  D  4183  million,  50%  of
which  was  spent  on  inpatient  care  [1].  Two  main  reasons
explain  this  considerable  cost.  Firstly,  there  has  been  a  huge
increase  in  the  number  of  revascularization  procedures  (per-
cutaneous  coronary  intervention  [PCI]  and  coronary  artery
bypass  graft  [CABG]).  The  use  of  angioplasty  has  increased
rapidly  since  1990  in  most  European  countries,  becoming
the  preferred  method  of  revascularization  around  the  mid-
1990s.  Secondly,  the  unit  cost  of  PCI  has  increased  with  the
c
w
Nidespread  use  of  drug-eluting  stents  (DES).  Indeed,  DES
ave  been  the  most  important  change  in  the  management
f  CAD,  as  they  reduce  repeat  revascularizations  caused
y  restenosis,  compared  with  bare-metal  stents  (BMS).  In
rance  in  2013,  the  unit  cost  of  one  DES  was  approximately
wice  that  of  a  BMS.  In  real-life  situations,  however,  the  gen-
ralized  use  of  DES  has  not  led  to  the  expected  reduction  in
he  total  number  of  procedures  performed  [2].
Clinical  data  have  failed  to  demonstrate  clear  superiority
f  any  of  the  treatment  modalities  available  (medical  ther-
py  alone,  PCI  or  CABG)  for  stable  CAD  in  terms  of  hard
linical  events  for  non-speciﬁc  populations  (i.e.  patients
ith  diabetes,  peripheral  artery  disease,  etc.)  [3—7].
umerous  studies  have  assessed  the  cost-effectiveness  of
5 T.  Caruba  et  al.
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Figure 1. Clinical scenarios after 1 year of follow-up. CABG: coro-
nary artery bypass graft; MI: myocardial infarction; OMT: optimal
medical therapy; p: probability of a patient being in one of the six
clinical scenarios after 1 year of follow-up; PCI-BMS: percutaneous
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he  different  pairwise  therapeutic  options.  There  was  no
ifference  in  the  cost-effectiveness  ratio  after  4  years  of
ollow-up  between  DES  versus  BMS  in  the  ENDEAVOR  II  trial
8]  and  between  PCI  versus  contemporary  medical  ther-
py  in  the  COURAGE  trial  [9].  According  to  the  results  of
he  SYNTAX  trial,  there  was  a  signiﬁcant  difference  in  the
ost-effectiveness  ratio  in  favor  of  DES  after  1  year  and
ABG  after  5  years  of  follow-up  [10,11].  Several  variables
xplain  the  disparity  in  results  of  cost-effectiveness  stud-
es:  the  number  and  complexity  of  stenoses;  the  duration
f  patient  follow-up;  the  changes  in  treatments  over  time;
nd  the  lack  of  studies  comparing  all  four  treatments  simul-
aneously  [12].  In  this  context,  the  goal  of  our  study  was
o  determine  the  costs  of  the  four  conventional  treatment
odalities  (drugs  alone,  PCI  with  BMS  [PCI-BMS],  PCI  with
ES  [PCI-DES]  and  CABG),  including  ambulatory  and  hospital
osts,  to  French  statutory  health  insurance.  We  determined,
rst,  the  annual  cost  of  different  ‘‘clinical  scenarios’’  (ther-
peutic  successes  or  failures)  for  each  of  the  four  usual
reatments  for  patients  with  stable  CAD:  optimal  medical
herapy  (OMT),  PCI-BMS,  PCI-DES  and  CABG.  The  second  aim
f  our  study  was  to  determine  the  average  annual  cost  of
ach  of  these  four  usual  treatments,  taking  into  account  the
robability  of  occurrence  of  the  different  clinical  scenarios.
hese  costs  were  determined  using  a  modeling  approach,
rom  the  perspective  of  the  French  national  payer.
ethods
ethodology overview
e  ﬁrst  determined  the  possible  clinical  course  over  1  year
f  any  stable  coronary  patient,  deﬁning  different  clinical
cenarios  after  one  of  the  four  usual  CAD  treatments:  OMT,
CI-BMS,  PCI-DES  and  CABG.  We  then  determined  the  quanti-
ies  of  care  consumed  during  1  year  for  each  of  these  clinical
cenarios  after  each  of  the  four  treatments.  Using  the  unit
rice  of  health  care  consumed,  we  calculated  the  cost  of
ach  clinical  scenario.  In  a  second  step,  we  determined  the
robability  of  each  clinical  scenario  depending  on  the  treat-
ent  performed.  Using  the  probability  of  each  scenario  and
ts  cost,  the  total  1-year  cost  incurred  by  statutory  health
nsurance  for  each  treatment  strategy  was  determined.
tudy population
he  study  population  comprised  male  and  female  patients,
ged  between  50  and  70  years,  with  stable  CAD,  deﬁned  as
on-acute  heart  disease  (i.e.  no  acute  coronary  syndrome
r  myocardial  infarction  [MI]  in  the  last  24  hours).
etermination of clinical scenarios
e  deﬁned  six  different  clinical  scenarios  that  could  occur
ver  1  year  in  any  patient  with  stable  CAD:  clinical  success,
ecurrence  of  symptoms  without  hospitalization  or  revas-
ularization,  MI,  subsequent  revascularization  without  MI,
eath  from  non-cardiac  cause,  and  cardiac  death.  Clini-
al  success  was  deﬁned  as  the  absence  of  the  ﬁve  other
ituations  (Fig.  1).  A  total  of  24  possibilities  thus  existed
t
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Woronary intervention with bare-metal stent; PCI-DES: percutaneous
oronary intervention with drug-eluting stent.
six  clinical  scenarios  for  each  of  the  four  initial  treatment
ptions).
The  probability  of  a  patient  being  in  one  of  the  six  clinical
cenarios  after  1  year  of  follow-up,  according  to  the  initial
reatment  used,  was  determined  from  a  literature  search.
he  probabilities  derived  from  published  data  were  then  val-
dated  by  an  expert  committee  (three  cardiologists  highly
xperienced  in  angina  management  and  working  in  three
ifferent  hospitals  [Y.J.,  O.D.  and  N.D.]).  Probabilities  of  a
iven  clinical  scenario  that  could  not  be  determined  from
he  literature  were  agreed  upon  by  consensus  of  the  three
xperts.
The  literature  search  was  performed  on  PubMed  for  publi-
ation  dates  ranging  from  1990  to  01  June  2012.  The  keyword
‘stable  angina’’  was  combined  with  one  of  the  three  fol-
owing  keywords  ‘‘stents  [MeSH]’’,  ‘‘coronary  artery  bypass
MeSH]’’  or  ‘‘drug  therapy  [MeSH]’’.  The  following  inclusion
riteria  were  applied:  randomized  or  observational  studies;
t  least  one  of  the  four  treatments  investigated;  clinical
ata  available  at  1  year  follow-up  (rate  of  recurrence  of
ymptoms  and/or  MI  and/or  revascularization  and/or  car-
iac  death  and/or  non-cardiac  death);  and  studies  with  at
east  50%  of  patients  with  multivessel  disease,  to  make  com-
arison  of  all  therapeutic  methods  appropriate.  We  excluded
tudies  conducted  exclusively  on  patients  with  diabetes  mel-
itus.
We  read  the  titles  and  abstracts  of  2443  electronic  ref-
rences.  Among  them,  the  full  text  of  21  were  read  and
2  were  selected:  ARTS  (Arterial  Revascularization  Therapy
tudy)  [13,14];  CABRI  (Coronary  Angioplasty  versus  Bypass
evascularisation  Investigation)  [15];  COURAGE  (Optimal
edical  Therapy  with  or  without  PCI  for  Stable  Coronary
isease)  [16];  ERACI  (Argentine  Randomized  Trial  of  Percu-
aneous  Transluminal  Coronary  Angioplasty  versus  Coronary
rtery  Bypass  Surgery  in  Multivessel  Disease)  [17];  e-SELECT
egistry  (Sirolimus-eluting  Coronary  Stents  in  an  Unselected
orldwide  Population)  [18];  Euro  Heart  Survey  [19]; GABI
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(the  German  Angioplasty  Bypass  Surgery  Investigation)  [20];
MASS  II  (The  Medicine,  Angioplasty,  or  Surgery  Study  II)  [21];
SoS  (the  Stent  or  Surgery  trial)  [22];  SPIRIT  III  (Comparison
of  an  Everolimus-Eluting  Stent  and  a  Paclitaxel-Eluting  Stent
in  Patients  With  Coronary  Artery  Disease)  [23];  SYNTAX  (Syn-
ergy  between  PCI  with  Taxus  and  Cardiac  Surgery)  [24]; and
the  SYNTAX  PCI  and  CABG  registries  [25].
Costing method
Direct  medical  costs  were  estimated  for  1  year  and  cal-
culated  from  the  resources  used  from  the  perspective  of
French  statutory  health  insurance.  Only  costs  related  to
treatment  and  complications  were  studied.  Costs  were
expressed  in  2012  euros  (D  ).  Because  all  the  costs  calcu-
lated  were  based  upon  reimbursements  paid  by  statutory
health  insurance,  these  costs  actually  represent  tariffs.  We
worked  exclusively  on  reimbursement  tariffs  granted  to  pub-
lic  hospitals.
Health care consumption
Quantities  of  care  consumed  were  determined  from  guide-
lines,  assuming  those  guidelines  were  actually  followed,  and
from  clinical  studies.  If  no  information  was  available  in  the
guidelines  or  in  clinical  studies,  consensus  was  reached  by
the  three  expert  cardiologists.  The  recommendations  used
were:  ‘‘diagnosis  and  management  of  patients  with  sta-
ble  ischemic  heart  disease’’  (American  Heart  Association,
2012);  ‘‘coronary  heart  disease  procedures  and  services’’
(Haute  Autorité  de  Santé,  2012);  and  ‘‘guidelines  on  the
management  of  stable  angina  pectoris’’  (European  Society
of  Cardiology,  2006)  [26—28].
Resources  used  were  related  to  the  treatment  studied
(OMT,  PCI-BMS,  PCI-DES  or  CABG)  and  subsequent  care  over
1  year  of  follow-up  to  manage  therapeutic  success  or  occur-
rence  of  complications.
Treatment  studied
For  the  four  treatments  studied,  drugs  in  the  fol-
lowing  therapeutic  classes  were  used:  aspirin,  statins,
angiotensin-converting  enzyme  inhibitors,  beta-blockers,
calcium  channel  blockers,  nitrates  and  clopidogrel.  The  pro-
portions  of  patients  treated  with  each  medication  class
t
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Table  1  Proportions  of  patients  receiving  medications  over  1  
OMT  
COURAGE  [16]  
Aspirin  (12  months)  95%  
Statin  (12  months)  95%  
ACE  inhibitor  (12  months)  62%  
Beta-blocker  (12  months)  89%  
Calcium  channel  blocker  (12  months)  49%  
Nitrates  (12  months)  67%  
Clopidogrel  (1  month)  —  
Clopidogrel  (12  months)  —  
ACE: angiotensin-converting enzyme; CABG: coronary artery bypass gr
percutaneous coronary intervention with bare-metal stent; PCI-DES: pe
a Based on the percentage of consumption of aspirin.ing  study  579
ame  from  the  COURAGE  and  SYNTAX  studies  [16,24],  and
re  presented  in  Table  1.  Drugs  were  assumed  to  be  con-
umed  for  1 year  for  the  four  treatments  studied,  except  for
lopidogrel,  which  was  assumed  to  be  taken  for  1  month  in
ase  of  treatment  with  PCI-BMS.  For  each  drug,  we  assumed
hat  the  quantity  consumed  corresponded  to  the  World
ealth  Organization  ‘‘deﬁned  daily  dose’’  (DDD).  In  case
f  revascularization  with  PCI,  we  set  the  number  of  stents
er  procedure  at  1.5  ±  0.8,  in  line  with  the  average  ﬁgure
ecorded  in  the  national  observational  study  of  diagnostic
nd  interventional  cardiac  catheterization  (ONACI)  [29].
ubsequent  care  over  1  year
esources  consumed  belonged  to  three  categories:  ambu-
atory  care;  hospitalization  for  complications;  and  medical
ransport.  Resources  used  in  the  six  clinical  scenarios  varied
nd  are  summarized  in  Table  2.
Regarding  ambulatory  care,  for  the  four  treatments,  and
or  all  clinical  scenarios,  average  consumption  over  1  year
as  set  at:  four  consultations  with  a  general  practitioner;
ne  consultation  with  a  cardiologist  with  performance  of
 resting  electrocardiogram  and  a  stress  electrocardio-
ram;  and  laboratory  tests,  including  lipid  proﬁle,  fasting
lood  glucose,  plasma  creatinine  and  a  blood  cell  count.
n  addition,  for  the  ‘‘recurrence  of  symptoms  without
evascularization  or  hospitalization’’  scenario,  whatever
he  treatment  modality,  guidelines  recommend  that  the
atients  consult  their  physicians,  without  deﬁning  the  fre-
uency  of  the  visits;  we  hypothesized  that  patients  in  this
linical  situation  had  two  visits  with  their  cardiologists  dur-
ng  the  year.  As  guidelines  also  recommend  in  this  clinical
cenario  performance  of  non-invasive  and/or  invasive  test-
ng,  we  proposed  the  following:  stress  echocardiography  in
5%  of  patients;  radionuclide  myocardial  perfusion  imaging
n  25%;  echocardiography  and  coronary  angiography  in  25%;
nd  myocardial  perfusion  imaging  and  coronary  angiography
n  25%.
Regarding  hospitalization  for  complications,  for  patients
ith  the  clinical  scenario  ‘‘MI’’,  according  to  the  data  of
he  French  registry  FAST-MI,  we  knew  that  77%  had  been
ospitalized  with  the  French  diagnosis-related  group  (DRG)
ntitled  ‘‘stent  with  MI’’  [30].  In  addition,  according  to
he  ONACI  data,  we  assumed  that  the  number  of  stents
year,  according  to  treatment  strategy.
PCI-BMS  PCI-DES  CABG
COURAGE  [16]  SYNTAX  [24]  SYNTAX  [24]
95%  91%  84%
93%  87%  75%
64%  55%  45%
85%  81%  79%
40%  26%  18%
53%  NA  NA
95%a —  —
—  71%  15%
aft; NA: not available; OMT: optimal medical therapy; PCI-BMS:
rcutaneous coronary intervention with drug-eluting stent.
580  T.  Caruba  et  al.
Table  2  Proportions  of  patients  using  health  care  resources  over  1  year,  according  to  clinical  scenario.
Clinical
success
Recurrent
symptoms
MI  Revascularization  Non-cardiac
death
Cardiac
death
Ambulatory  care
Four  GP  visits  and  one  cardiologist  visit  100%  100%  100%  100% 100%  100%
One  resting  ECG  and  one  exercise  ECG  100%  100%  100%  100% 100%  100%
One  laboratory  testa 100%  100%  100%  100% 100%  100%
Second  visit  to  cardiologist 100%
Echocardiography  25%
Myocardial  perfusion  imaging 25%
Echocardiography  and  coronary
angiography
25%
Myocardial  perfusion  imaging  and
coronary  angiography
25%
Hospitalization
MI  100%
CABG  ±  cardiac  catheterization  or
coronary  angiography
100%
Death  during  a  non-cardiac
hospitalization
63%
Death  during  a  cardiac  hospitalization  48%
Medical  transport
Emergency  medical  services  (SAMU)  74%  0% 40%  74%
Private  ambulance  14%  21%  10%  14%
Fire  brigade  12%  0% 40%  12%
Medical  taxi  0%  7% 10%  0%
CABG: coronary artery bypass graft; ECG: electrocardiogram; GP: general practitioner; MI: myocardial infarction; SAMU: Service d’Aide
Médicale Urgente.
a Lipid proﬁle, plasma creatinine, haemogram and fasting glucose.
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1mplanted  per  patient  was  1.5  ±  0.8  and  that  55%  of  stents
mplanted  were  BMS  [29].  For  the  remaining  23%  of  patients
n  the  clinical  scenario  ‘‘MI’’,  we  considered  that  they  had
ot  been  revascularized  and  that  they  were  hospitalized
ith  the  DRG  entitled  ‘‘MI’’.  All  patients  with  the  clinical
cenario  ‘‘revascularization  without  MI’’  were  hospitalized
ccording  to  the  DRG  with  one  of  these  items:  ‘‘CABG  with
ardiac  catheterization  or  coronary  angiography’’  or  ‘‘stent
ithout  MI’’.  Moreover  for  the  ‘‘stent  without  MI’’  DRG,  we
lso  added  the  number  of  implanted  stents  according  to  data
rom  ONACI  (i.e.  1.5  ±  0.8).
Because  two  French  national  databases  used  death  cer-
iﬁcates  (Inserm-CépiDC,  which  studied  medical  cause  of
eath  in  and  out  hospital  [31],  and  the  French  Programme  of
edicalization  of  Information  Systems  [programme  médical-
sé  des  systèmes  d’informations;  PMSI]  [32])  we  knew  that
mong  patients  who  died  of  a  non-cardiac  cause  in  2012  (i.e.
linical  scenario  ‘‘non-cardiac  death’’),  63%  died  in  hospi-
al.  Among  patients  who  died  from  a  cardiac  cause  (clinical
cenario  ‘‘cardiac  death’’),  48%  died  during  inpatient  stay.
e  assumed  in  our  models  that  the  dead  patients  died  on
he  365th  day  of  follow-up.  Therefore,  dead  patients  were
upposed  to  have  consumed  all  planned  care  (inpatient  and
utpatient),  as  would  patients  who  were  alive  at  the  end  of
he  ﬁrst  year.
Regarding  medical  transport,  reimbursed  transport  to  the
ospital  could  be  used  in  all  clinical  scenarios  requiring
C
T
v
Fospital  admissions  (i.e.  ‘‘MI’’,  ‘‘revascularization  without
I’’,  ‘‘non-cardiac  death’’  and  ‘‘cardiac  death’’).  Accord-
ng  to  the  personal  data  of  the  principal  investigator  of
AST-MI,  patients  with  ‘‘MI’’  used  emergency  medical  ser-
ices  in  74%  of  cases,  private  medical  ambulances  in  14%
nd  the  ﬁre  brigade  in  12%.  According  to  an  unpublished
tudy  performed  in  our  hospital,  patients  hospitalized  for
n  elective  ‘‘revascularization  without  MI’’  (PCI  or  CABG)
sed  private  medical  ambulances  in  21%  of  cases  and  a  reim-
ursed  taxi  in  7%.  Other  patients  used  their  own  transport.
ecause  there  are  no  French  data  about  medical  transport
sed  by  patients  in  the  clinical  scenario  ‘‘cardiac  death’’,
e  assumed  these  patients  used  the  same  transport  as  the
‘MI’’  patients.  Finally,  for  ‘‘non-cardiac  death’’,  which  rep-
esents  a large  variety  of  serious  diseases,  we  hypothesized
hat  patients  used  emergency  medical  services  or  the  ﬁre
rigade  overwhelmingly,  which  is  why  we  ﬁxed  the  following
roportions  for  medical  transport  in  this  clinical  situation:
mergency  medical  services  in  40%  of  cases,  the  ﬁre  brigade
n  40%,  private  ambulances  in  10%  and  reimbursed  taxis  in
0%.ost of health care resources
he  unit  costs  of  outpatient  medical  products  and  ser-
ices  and  of  hospitalization  were  based  on  the  costs  to
rench  statutory  health  insurance  [31—33]. All  costs  were
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Table  3  Unit  daily  cost  for  each  drug  according  to  deﬁned  daily  dose,  and  proportions  of  brand  name  and  generic
versions  available  through  MEDIC’AM  (2012).
Drugs  by  therapeutic  class  DDD  (mg)  Proportion  available  Unit  price  (D  ) Unit  cost/
day  (D  )
B  G  B  G
Platelet  aggregation  inhibitors
Acetylsalicylic  acid  1  tablet;  75  or
160
100% 0% 0.1  —  0.1
Clopidogrel  75  38%  62% 1.4  0.9  1.09
Statins
Pravastatin 30  10% 90% 1.0 0.7 0.7
Simvastatin  30  7% 93% 1.1 0.7 0.7
Fluvastatin  60  47% 53% 0.7 0.7 0.7
Atorvastatin  20  100%  0% 1.2  —  1.2
Rosuvastatin  10  100%  0% 1.2  —  1.2
ACE  inhibitors
Captopril  50  17%  83% 0.5  0.3  0.3
Enalapril  10  20%  80% 0.8  0.8  0.8
Lisinopril  10  20%  80% 0.6  0.6  0.6
Perindopril 4  66%  34% 0.7  0.5  0.6
Ramipril  2.5  13% 87% 0.5  0.3  0.3
Trandolapril 2  58%  42% 0.3  0.3  0.3
Quinapril  15  48% 52% 0.6  0.4  0.5
Beta-blockers
Atenolol  75  13%  87% 0.3  0.2  0.2
Acebutolol  400  22%  78% 0.4  0.3  0.3
Metoprolol  150  66%  34% 0.2  0.1  0.2
Bisoprolol  10  29%  71% 0.2  0.2  0.2
Carvedilol  37.5  58%  42% 0.6  0.6  0.6
Propranolol  160  13%  87% 0.3  0.3  0.3
Celiprolol  200  16%  84% 0.4  0.3  0.3
Calcium  channel  blockers
Diltiazem  240  74%  26% 0.9  0.5  0.8
Verapamil  240  43%  57% 0.3  0.3  0.3
Amlodipine  5  15%  85% 0.5  0.3  0.3
Felodipine  5  23%  77% 0.4  0.2  0.2
Nifedipine  30  59%  41% 0.4  0.4  0.4
Nitrates
Isosorbide  dinitrate  60  79%  21% 0.1  0.02  0.1
Isosorbide  mononitrate  40  100%  0% 0.1  —  0.1
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tACE: angiotensin-converting enzyme; B: brand name; DDD: deﬁne
calculated  for  2012  from  the  perspective  of  the  French
national  payer.
To calculate  the  cost  related  to  the  use  of  drugs,  we  ﬁrst
calculated  the  daily  unit  cost  of  each  drug  that  is  potentially
useful  in  the  treatment  of  CAD  (i.e.  atorvastatin,  diltiazem,
clopidogrel,  etc.);  for  each  drug  we  multiplied  the  DDD
by  its  unit  price,  weighted  by  the  available  proportions  of
brand  name  and  generic  versions  (available  from  the  French
database  MEDIC’AM  [34])  (Table  3).  Then,  we  calculated  the
unit  cost  of  each  therapeutic  class  (e.g.  the  daily  unit  cost
of  statins).  To  do  this  we  multiplied  the  daily  unit  cost  of
each  drug  belonging  to  the  same  therapeutic  class  by  the
proportion  of  each  drug  in  this  therapeutic  class  (data  from
the  MEDIC’AM  database)  (Table  4).
C
u
tly dose; G: generic.
To  calculate  the  cost  of  hospitalization  for  an  angioplasty
ith  a  BMS  or  DES,  we  considered  the  number  of  patients  in
ach  DRG  entitled  ‘‘stent  without  MI’’.  There  are  ﬁve  such
RGs,  according  to  the  level  of  severity  of  co-morbidities
f  the  patients  (relevant  DRGs:  05K061,  05K062,  05K063,
5K064,  05K06T).  For  each  severity  level,  the  proportion  of
atients  was  known  from  the  PMSI  national  database.  We
alculated  the  mean  cost  of  PCI  and  its  standard  deviation
sing  these  data.  Next,  we  had  to  add  the  cost  related  to
he  stent  implantation;  the  unit  cost  for  the  stent  came  from
he  LPPR  (liste  des  produits  et  prestations  remboursables).
odes  used  for  BMS  were  3142930  and  3180468,  and  codes
sed  for  DES  were  3103976  and  3166310;  these  codes  are
hose  for  the  highest  and  lowest  price  for  each  stent.
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Table  4  Distribution  of  each  drug  when  there  were  dif-
ferent  drugs  in  the  same  therapeutic  class  (MEDIC’AM
2012).
Drugs  by  therapeutic  class Distribution  of
each  drug
Statins
Pravastatin 19%
Simvastatin  18%
Fluvastatin  4%
Atorvastatin  32%
Rosuvastatin  27%
ACE  inhibitors
Captopril  3%
Enalapril  7%
Lisinopril  6%
Perindopril  36%
Ramipril  43%
Trandolapril  4%
Quinapril  1%
Beta-blockers
Atenolol  19%
Acebutolol  14%
Metoprolol  5%
Bisoprolol  39%
Carvedilol  2%
Propranolol  14%
Celiprolol  7%
Calcium  channel  blockers
Diltiazem  22%
Verapamil  22%
Amlodipine  47%
Felodipine  4%
Nifedipine  5%
Nitrates
Isosorbide  dinitrate  22%
Isosorbide  mononitrate  78%
ACE: angiotensin-converting enzyme.
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D  396  with  the  brand  name  version  and  D  252  with  theUsing  the  same  method  as  for  angioplasty,  we  calculated
he  mean  cost  of  a  hospitalization  for  CABG  (DRG:  05C041,
5C042,  05C043,  05C044)  and  its  standard  deviation.
Using  similar  methodology,  we  calculated  the  costs  for
omplications  requiring  hospitalization.  In  case  of  ‘‘MI’’,  for
7%  of  patients  the  DRG  used  was  ‘‘stent  with  MI’’  (codes
5K051,  052,  053  and  054)  and  for  the  others  the  DRG
sed  was  ‘‘MI’’  (codes  05M041,  05M042,  05M043,  05M044
nd  05M04T).  In  case  of  ‘‘revascularization  without  MI’’,
he  DRGs  used  were  ‘‘stent  without  MI’’  and  ‘‘CABG  with
ardiac  catheterization  or  coronary  angiography’’  (codes
5C041,  05C042,  05C043,  05C044,  05K061,  05K062,  05K063,
5K064,  05K06T).  For  the  clinical  scenario  ‘‘cardiac  death’’,
ll  DRGs  related  to  cardiology  were  selected.  To  calculate
he  cost  of  ‘‘non-cardiac  death’’,  we  extracted  from  the
ational  database  all  patients  who  had  died  during  a  hos-
italization,  and  who  were  hospitalized  for  a  non-cardiac
ause.
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Regarding  the  cost  of  transport,  emergency  medical  ser-
ices,  private  ambulance  and  medical  taxi  only  were  paid
y  the  French  national  payer.  The  ﬁre  brigade  are  not  paid
y  French  statutory  health  insurance.  Costs  of  transport  in
able  5  corresponded  to  a  round  trip  from  home  to  hospital
trip  length  was  estimated  as  being  between  5  and  20  km).
All  unit  costs  are  summarized  in  Table  5.
odeling of cost per strategy and uncertainty
anagement
s  recommended  by  the  French  guidelines  for  economic
valuation  of  health  technologies  [35],  a  probabilistic  anal-
sis  using  Monte  Carlo  simulations  was  used  to  manage
ncertainty  in  health  care  resources  costs  and  the  prob-
bilities  of  occurrence  of  clinical  scenarios.  Probabilistic
ensitivity  analyses  were  performed  using  gamma  distribu-
ions  for  hospitalization  cost  [36], uniform  distributions  for
edication  costs,  Poisson  distribution  for  the  number  of
tents  used  and  normal  distributions  for  the  probabilities
f  each  clinical  scenario  with  each  treatment  performed.
One  thousand  virtual  patients  were  simulated  for  each
reatment  strategy  assessed.  We  set  the  seed  so  that  the
ame  iteration  for  each  strategy  gave  the  same  value  for
he  same  parameter;  this  ensured  comparability  of  thera-
eutic  strategies.  We  then  calculated  the  difference  in  cost
etween  the  different  therapeutic  strategies.  In  order  to
ompute  the  conﬁdence  interval  of  the  cost  of  the  strate-
ies,  we  performed  100  bootstraps  of  the  samples  of  each
reatment  strategy  created  with  the  Monte  Carlo  simulation;
his  created  100  samples  of  1000  patients  for  each  strategy,
or  which  we  calculated  the  position  and  dispersion  param-
ters.
A  patient-level  cost  simulation  model  using  R  statistical
oftware  was  constructed  to  compare  the  four  treatment
trategies.
esults
robabilities of clinical scenarios according to
nitial treatment strategy
able  6  presents  the  probabilities  of  each  clinical  sce-
ario  for  the  different  treatment  modalities.  No  value  for
he  probability  of  the  clinical  scenario  p2  ‘‘recurrence
f  symptoms’’  was  found  in  the  literature.  According
o  the  three  experts,  the  probability  of  p2  was  ﬁxed
t  10%  of  p1  for  patients  treated  by  revascularization
5—15%),  and  at  17.5%  of  p1  for  patients  treated  with  OMT
10—25%).  For  all  treatments,  p1  was  calculated  as  follows:
00  −  (p2  +  p3  +  p4  +  p5  +  p6).
nit costs
or  each  drug,  except  for  aspirin,  unit  costs  may  vary  con-
iderably,  depending  on  the  existence  or  not  of  a  generic
ersion.  For  example,  with  simvastatin,  the  annual  cost  waseneric  version.  Taking  into  account,  on  the  one  hand,  the
roportion  of  generic  and  brand  name  versions  available
or  each  drug  and,  on  the  other  hand,  the  proportion  of
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Table  5  Unit  costsa for  health  care  resources  used  (2012).
Fixed  cost  (D  )  Mean  cost  (D  )  SD  (D  )
Treatment
Aspirin  (1  day  of  treatment)  0.1
Clopidogrel  (1  day  of  treatment) 1.1
Statin  (1  day  of  treatment) 1
ACE  inhibitor  (1  day  of  treatment)  0.5
Beta-blocker  (1  day  of  treatment)  0.2
Calcium  channel  blocker  (1  day  of  treatment)  0.4
Nitrate  (1  day  of  treatment)  0.1
PCI  2918  1623
BMS  (one  stent)  700  150
DES  (one  stent)  1125  25
CABG  15,237  5706
Ambulatory  care
One  GP  visit  22
One  cardiologist  visit  49
One  ECG  stress  test  76
One  laboratory  testb 19
Echocardiography  147
Myocardial  perfusion  imaging 778
Echocardiography  and  coronary  angiography  391
Myocardial  perfusion  imaging  and  coronary  angiography 1022
Hospitalization  for  complication
MI  3941  1514
Revascularization  (CABG  or  stent)  4317  4616
Hospitalization  with  a  non-cardiac  death  9290  11,794
Hospitalization  with  a  cardiac  death  9230  13,065
Medical  transport
Emergency  medical  service  (SAMU)  840
Private  ambulance  105
Medical  taxi  60
Public  ambulance  0
ACE: angiotensin-converting-enzyme; BMS: bare-metal stent; CABG: coronary artery bypass graft; DES: drug-eluting stent; ECG: elec-
trocardiogram; GP: general practitioner; MI: myocardial infarction; PCI: percutaneous coronary intervention; SAMU: Service d’Aide
Médicale Urgente; SD: standard deviation.
a Those costs are net of the share remaining the responsibility of each patient (D 1 per medical visit, D 0.50 per box of drugs, D 18 per
hospitalization, etc.).
b Lipid proﬁle, plasma creatinine, haemogram and fasting glucose.
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veach  drug  in  the  same  therapeutic  class,  the  annual  cost
for  each  therapeutic  class  was:  D  402  for  clopidogrel,  D  365
for  statins,  D  183  for  ACE  inhibitors,  D  146  for  calcium  chan-
nel  blockers,  D  73  for  beta-blockers,  and  D  37  for  nitrates
and  aspirin.  The  mean  cost  for  a  hospitalization  with  PCI
was  D  2918,  to  which  stent-related  costs  have  to  be  added.
The  mean  cost  for  one  stent  was  D  700  for  a  BMS  (range
D  550—850)  and  D  1125  for  a  DES  (range  D  1100—1150).
Therefore,  the  overall  mean  cost  of  a  hospitalization  for
PCI  was  D  3968  when  BMS  were  used  and  D  4605  when
DES  were  used.  The  mean  cost  of  a  hospitalization  with
CABG  was  D  15,237.  Costs  related  to  hospitalization  for  a
complication  were:  D  3941  in  case  of  MI,  D  4317  in  case
of  revascularization  (by  PCI  with  stent  or  CABG),  D  9290
in  case  of  non-cardiac  death  and  D  9230  in  case  of  car-
diac  death.  The  unit  cost  of  medical  transport  ranged  from
c
w
e 60  for  a  medical  taxi  to  D  840  for  an  emergency  medical
ervice.
ost of each clinical scenario according the
reatment performed
able  7  presents,  for  the  four  treatments  studied,  the  costs
f  each  clinical  scenario,  independent  of  their  probability  of
ccurring.  The  mean  cost  of  a  success  after  1  year  of  follow-
p  was:  D  855  with  OMT,  D  4796  with  PCI-BMS,  D  5639  with
CI-DES  and  D  15,968  with  CABG.  The  95%  conﬁdence  inter-
als  (CIs)  did  not  overlap  (P  <  0.05).For  the  four  treatments  studied,  the  order  of  the  annual
osts  of  six  clinical  scenarios  was  the  same:  clinical  success
as  the  least  expensive  and  non-cardiac  death  was  the  most
xpensive.
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Table  6  Probabilities  of  clinical  events  according  to  normal  distributions  of  each  clinical  scenario  with  the  four  treatment  strategies  over  1  year  of  follow-up,  as
determined  by  data  from  references  or  expert  consensus.
OMT  PCI-BMS  PCI-DES  CABG
Mean  ±  SD  Source  Mean  ±  SD  Source  Mean  ±  SD  Source  Mean  ±  SD  Source
p2  0.0175  ×  p1  Experts  0.010  ×  p1  Experts  0.010  ×  p1  Experts  0.010  ×  p1  Experts
p3  0.035  ±  0.004  [16,19,21]  0.053  ±  0.008  [13,14,19,21,22]  0.048  ±  0.005  [18,23—25]  0.047  ±  0.006  [13—15,17,20,22,25]
p4  0.064  ±  0.003  [16,19,21]  0.128  ±  0.021  [13,14,16,19,21,22]  0.088  ±  0.012  [18,23—25]  0.045  ±  0.003  [13—15,17,20,22,25]
p5  0.013  ±  0.0001  [16]  0.012  ±  0.0001  [13,14,16,19,21,22]  0.016  ±  0.002  [18,23—25]  0.009  ±  0.001  [13,14,16,22,25]
p6  0.01  ±  0.001  [16,21]  0.024  ±  0.005  [13,14,16,19,21,22]  0.03  ±  0.004  [18,23—25]  0.012  ±  0.002  [13,14,16,22,25]
CABG: coronary artery bypass graft; OMT: optimal medical therapy; p1: probability of having a clinical success; p2: probability of having recurrence of symptoms without revascularization
or hospitalization; p3: probability of having a myocardial infarction; p4: probability of having a revascularization; p5: probability of having a non-cardiac death; p6: probability of having
a cardiac death; PCI-BMS: percutaneous coronary intervention with bare-metal stent; PCI-DES: percutaneous coronary intervention with drug-eluting stent; SD: standard deviation.
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Table  7  Cumulative  ﬁrst-year  costs  for  each  clinical  scenario  according  to  treatment  strategy,  irrespective  of  the
probabilities  of  each  clinical  scenario  (2012).a
OMT  PCI-BMS  PCI-DES  CABG
Clinical  success  (D  ) 855  (848—861)  4796  (4698—4894)  5639  (5532—5746)  15,968  (15,602—16,334)
Recurrent  symptoms
without
revascularization
or hospitalization
(D  )
1417  (1395—1439)  5359  (5261—5456)  6201  (6097—6305)  16,531  (16,168—16,893)
MI  (D  )  5326  (5233—5418)  9267  (9106—9428)  10,110  (9939—10,280)  20,439  (20,046—20,832)
Revascularization
(D  )
5827  (5609—6044)  9768  (9514—10022)  10,611  (10,342—10,880)  20,940  (20,474—21,406)
Non-cardiac  death
(D  )
6798  (6322—7274) 10,740  (10,245—11,234) 11,582  (11,092—12,072) 21,911  (21,329—22,493)
Cardiac  death  (D  )  5636  (5258—6014)  9578  (9200—9955)  10,420  (10,039—10,801)  20,749  (20,240—21,259)
CABG: coronary artery bypass graft; MI: myocardial infarction; OMT: optimal medical therapy; PCI-BMS: percutaneous coronary
intervention with bare-metal stent; PCI-DES: percutaneous coronary intervention with drug-eluting stent.
a Data are expressed as mean (95% conﬁdence interval).
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TCost of each treatment modality taking into
account probabilities of occurrence of each
clinical scenario
After  1  year  of  follow-up,  and  when  the  probabilities  of  the
six  clinical  scenarios  were  integrated  in  our  models,  mean
costs  per  patient  were  D  1567  with  OMT,  D  5908  with  PCI-
BMS,  D  6623  with  PCI-DES  and  D  16,612  with  CABG.  These
costs  were  signiﬁcantly  different  (P  <  0.05)  (Table  8).
When  analyzing  the  distribution  of  costs  for  each  ther-
apeutic  option,  the  most  expensive  component  was  the
treatment  studied  itself  (drugs,  PCI  or  CABG),  and  the  sec-
ond  was  hospitalizations  for  complications  (Table  8).  The
cost  of  the  treatment  studied  represented  between  41%  and
95%  of  the  mean  annual  cost  of  the  therapeutic  option  (41%
for  OMT  and  95%  for  CABG);  95%  CIs  did  not  overlap.  For
the  four  treatments  studied,  the  costs  of  hospitalization
l
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Table  8  Total  cost  breakdown  by  type  of  expenditure,  accord
OMT  PCI-BMS  
Cost  related  to  initial
treatment  strategy  per
se  (drugs  alone  or
combined  with
revascularization)  (D  )
635  (628—641)  4576  (4480—
Hospitalization  for
complication  (MI,
revascularization  or
death)  (D  )
602  (459—746)  1017  (838—
Ambulatory  care  (D  )  294  (280—308)  257  (246—
Transport  (D  )  36  (27—45)  58  (48—6
Total  cost  (D  )  1567  (1421—1713)  5908  (5699—
CABG: coronary artery bypass graft; MI: myocardial infarction; OM
intervention with bare-metal stent; PCI-DES: percutaneous coronary in
a Data are expressed as mean (95% conﬁdence interval).or  complications  (management  of  MI  or  revascularization
ithout  MI  or  death)  were  the  second  most  expensive  item,
anging  from  3%  to  38%  of  the  annual  cost  (3%  for  CABG  and
8%  for  OMT).  For  CABG,  the  costs  related  to  hospitalization
or  complications  were  signiﬁcantly  different  from  those
or  PCI,  whatever  the  type  of  stent  used  (P  <  0.05).  These
osts  were  not  different  between  the  two  PCI  techniques
P  >  0.05).
iscussion
o  the  best  of  our  knowledge,  this  is  the  ﬁrst  study  calcu-
ating  and  comparing  the  annual  costs  of  four  treatments
ommonly  used  in  the  management  of  stable  CAD  in  France.
he  annual  costs  of  each  strategy,  according  to  their  efﬁ-
acy  results,  were  D  1567  with  OMT,  D  5908  with  PCI-BMS,
ing  to  treatment  strategy  (2012).a
PCI-DES  CABG
4673)  5419  (5311—5527)  15,749  (15,387—16,110)
1196)  892  (713—1071)  559  (430—689)
268)  258  (247—269)  258  (248—268)
8)  55  (46—64)  46  (37—54)
6118)  6623  (6409—6839)  16,612  (16,218—17,005)
T: optimal medical therapy; PCI-BMS: percutaneous coronary
tervention with drug-eluting stent.
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 6623  with  PCI-DES  and  D  16,612  with  CABG.  Our  results
how  that,  for  interventional  treatment  strategies,  the
ajority  of  the  costs  occurred,  as  expected,  during  the
ndex  hospitalization  to  perform  the  treatment.  The  lowest
osts  for  complications  were  observed  with  treatment  with
ABG.
The  annual  cost  of  OMT  may  seem  modest,  D  1567  per
atient,  with  only  D  635  for  medications,  which  was  based
pon  the  quantity  of  drugs  consumed  in  COURAGE  [16],  with
nly  62%  of  patients  treated  with  ACE  inhibitors  and  89%  with
eta-blockers  after  1  year  of  follow-up;  if  anything,  these
gures  in  stable  patients  are  likely  to  be  an  overestimation
f  the  medications  consumed  in  a  real-world  setting.  French
ata  in  patients  followed  6  months  after  an  MI  gave  results
hat  were  rather  similar  or  somewhat  lower  [37].
Our  results  show  high  variability  in  unit  prices  for  medica-
ions.  For  drugs,  unit  costs  may  vary  considerably,  depending
n  the  existence  or  not  of  generic  versions.  For  instance,
or  clopidogrel,  the  annual  cost  of  the  generic  version  is
 354  compared  with  D  585  for  the  brand  name  medication.
ikewise,  we  had  to  take  into  account  the  possibility  of  dif-
erent  drugs  belonging  to  the  same  therapeutic  class,  where
here  is  sometimes  high  variability  in  unit  prices.  The  annual
ost  for  a  patient  treated  with  rosuvastatin  (no  generic  ver-
ion  currently  available)  is  D  426,  while  the  annual  cost  with
eneric  ﬂuvastatin  is  D  222.
To  calculate  the  annual  costs  of  the  four  treatments,
e  considered  their  effectiveness  using  the  probability  of
ach  clinical  scenario  for  each  treatment.  In  our  models,
e  calculated  all  these  probabilities  using  normal  distribu-
ions  of  percentages  extracted  from  references.  After  1  year
f  follow-up,  for  the  clinical  scenario  ‘‘revascularization
ithout  MI’’,  this  probability  was  6.4%  for  treatment  with
MT,  12.8%  with  PCI-BMS,  8.8%  with  PCI-DES  and  4.5%  with
ABG  (Table  6).  This  probability  for  the  treatment  PCI-BMS
ay  seem  excessive  compared  with  treatment  with  OMT
ccording  to  the  results  of  COURAGE,  for  example  [16].
ut,  in  our  study,  according  to  the  literature  search  that
e  conducted  (see  Methods  above),  the  references  used
o  calculate  this  probability  for  the  treatment  with  OMT
ere  Euro  Heart  Survey,  MASS  II  and  COURAGE,  and  the
ate  of  ‘‘revascularization  without  MI’’  ranged  from  5%  to
.9%  [16,19,21].  For  the  PCI-BMS  treatment,  the  references
elected  were  Euro  Heart  Survey,  MASS  II,  COURAGE,  ARTS
nd  SoS,  and  the  rate  of  ‘‘revascularization  without  MI’’
anged  from  4.3%  to  21%  [13,14,16,19,21,22].
Finally,  our  results  are  consistent  with  economic  data
resented  in  international  randomized  trials  such  as
OURAGE  and  MASS  II,  where  OMT  potentially  allowed
ppreciable  savings  in  health  expenditures  to  be  achieved,
nd  was  a  cost-effective  approach  [9,38].
Knowing  the  cost  of  each  treatment  seems  important.  In
rance,  according  to  ONACI,  between  2004  and  2008,  the
ate  of  patients  treated  by  PCI  increased,  the  rate  of  OMT
lone  decreased  and,  ultimately,  the  rate  of  patients  treated
or  stable  angina  or  silent  ischemia  increased  [29].  Moreover,
ince  the  publication  of  the  Appropriate  Use  Criteria  for
ardiac  Revascularization,  a  rate  of  31%  to  49%  of  inappro-
riate  or  uncertain  revascularization  procedures  for  patients
ith  non-acute  indications  has  been  reported  [39].  Although
hese  rates  might  be  too  high  in  the  French  context,
t  is  important  that  clinicians  are  aware  that  potentially
S
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nnecessary  PCI  in  stable  CAD  has  a  cost;  our  results  can
e  used  to  estimate  these  inappropriate  expenses.
tudy limitations
everal  limitations  must  be  considered  when  interpreting
hese  results.  The  ﬁrst  is  that  our  study  is  based  upon  model-
ng,  and  we  had  to  estimate  the  quantity  of  ambulatory  care
onsumed,  as  well  as  the  quantity  of  medical  transport.  Our
ssumptions  were  largely  based  upon  international  or  non-
uropean  studies,  but  the  hypothetical  ﬁgures  we  retained
n  our  models  seemed  reasonable  to  all  three  expert  clini-
ians.  Moreover,  we  have  no  direct  estimate  to  ascertain  the
oding  quality  of  the  national  databases  used  for  our  mod-
ling.  It  is  well  known,  for  example,  that  death  certiﬁcates
re  often  of  limited  quality  concerning  the  documented
isease  leading  to  death  [40]. However,  in  the  absence  of
ore  valid  data,  death  certiﬁcates  and  publicly  available
ospital  statistics  are  accepted  information  sources  for  cost-
f-illness  studies.  Furthermore,  we  have  assumed  in  our
odels  that  the  dead  patients  died  on  the  365th  day  of  the
ear  and,  consequently,  consumed  all  planned  care  during
he  year  of  follow-up.  This  resulted  in  a  slight  overestima-
ion  of  total  costs,  but,  as  there  were  no  differences  in
ortality  between  the  four  treatment  options,  this  is  not
ikely  to  have  resulted  in  any  imbalance  when  comparing
he  costs  of  the  different  options.
Finally,  the  current  study  was  limited  to  a  1-year  perspec-
ive;  the  effect  of  each  strategy  on  outcomes  will  continue
ell  beyond  this  time  point.  In  fact,  limiting  cost  evalua-
ion  to  1  year  will  increase  the  relative  proportion  of  cost
elated  to  the  initial  revascularization  procedure,  and  will
herefore  somewhat  artiﬁcially  increase  the  relative  cost-
ffectiveness  of  any  strategy  not  needing  a costly  initial
ospital  stay:  the  cost-effectiveness  of  OMT  observed  in  the
urrent  study  is  likely  to  be  less  in  the  long  term  than  it  is
t  1  year.
onclusion
eeping  in  mind  that  all  four  treatment  options  are  clini-
ally  relevant  for  treating  stable  CAD,  depending  on  each
ndividual  real-life  clinical  situation,  OMT  appears  to  be  the
east  costly  option  over  1  year.  That  is  why,  if  reasonable
rom  a  clinical  point  of  view,  OMT  might  achieve  apprecia-
le  savings  in  health  expenditures  compared  with  invasive
reatments.  Although  limited  by  methodological  consider-
tions,  our  results  give  important  information  on  the  costs
f  the  different  treatment  modalities  for  stable  CAD.
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